1433 related articles for article (PubMed ID: 7583979)
1. Cellular immunotherapy of cancer.
Yang JC
Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
[TBL] [Abstract][Full Text] [Related]
2. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
Yannelli JR; Wroblewski JM
Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
[TBL] [Abstract][Full Text] [Related]
3. Adoptive T-cell immunotherapy of cancer.
Li Q; Chang AE
Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
7. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
9. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
11. Control mechanisms of cell-mediated reactions.
Salerno A; Sireci G; Dominici R; Bonanno CT; Caccamo N; Dieli F
Wien Klin Wochenschr; 1996; 108(8):244-7. PubMed ID: 8686315
[TBL] [Abstract][Full Text] [Related]
12. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
13. [Cellular immunotherapy of cancer].
Kawakami Y
Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813
[No Abstract] [Full Text] [Related]
14. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
15. Imaging the immune response to monitor tumor immunotherapy.
Wang Q; Ornstein M; Kaufman HL
Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
17. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy of tumors: from the first experimental studies to the recent clinical applications. I. Passive immunotherapy].
Burrai I; Di Lallo A
Minerva Med; 1991 Sep; 82(9):519-28. PubMed ID: 1944999
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of malignant melanoma.
Oratz R; Bystryn JC
Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
[TBL] [Abstract][Full Text] [Related]
20. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
